CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Millennium Pharmaceuticals Inc. v. Actavis Inc.

1:12-cv-01750

Overview

Case Number 1:12-cv-01750
Filing Date 2012-12-21
Status Terminated
Termination Date 2018-02-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Actavis Inc. Operating Company

Represented By

10 Attorneys Listed

Matt Neiderman

Duane Morris LLP

Tel: +1 (302) 657-4920

222 Delaware Avenue, Suite 1600

Jason James Rawnsley

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7550

Richards, Layton & Finger, PA, One Rodney Square

Pamela Avallone

UNDELIVERABLE EMAIL 2/4/15

Anthony J. Fitzpatrick

Email: AJFitzpatrick@duanemorris.com

Gary E. Hood

Email: ghood@polsinelli.com

Carolyn A. Alenci

Email: caalenci@duanemorris.com

Robyn H. Ast-Gmoser

Email: rastgmoser@polsinelli.com

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Vincent L. Capuano

Email: vcapuano@duanemorris.com

Laura A. Vogel

Email: lavogel@duanemorris.com

Plaintiff

Millennium Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2017-04-13
1:17-cv-00423

Millennium Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-04-13
1:17-cv-00422

Millennium Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2016-04-04
1:16-cv-00223

Millennium Pharmaceuticals Inc. v. Actavis LLC

U.S. Family Sibling (["US6713446"])
Status: DED
U.S. District Court 2015-09-10
1:15-cv-00804

Millennium Pharmaceuticals Inc. v. Hospira, Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-06-25
1:15-cv-00540

Millennium Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited

Asserted Patent
Status: DED
U.S. District Court 2015-01-14
1:15-cv-00039

Millennium Pharmaceuticals Inc. v. Hetero Labs Limited

Asserted Patent
Status: DED
U.S. District Court 2015-01-14
1:15-cv-00040

Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited

Asserted Patent
Status: DED
U.S. District Court 2014-01-22
1:14-cv-00093

Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-22
1:13-cv-00467

Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6713446
Formulation of boronic acid compounds
Filed: 2002-01-25
Issued: 2004-03-30
Expired (Term Ended)
Expires: 2022-01-25
US6958319
Formulation of boronic acid compounds
Filed: 2003-09-18
Issued: 2005-10-25
Expired (Term Ended)
Expires: 2022-04-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

7

Dispositive

0

Granted

0

Denied

0

Pending / Review

3

Motions by Category

Claim Construction / Markman Filing 3 Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
Official Transcript of Markman Hearing held on 10 31 13 before Judge Sleet. Court Reporter/Transcriber Maurer. Transcript may be viewed at the court public term...
Entry #23 • 2013-11-15 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 17 Joint STIPULATION TO EXTEND TIME to file a joint proposed protective order to April 11, 2013 filed by Millennium Pharmaceuticals Inc., Actavis...
Entry #β€” • 2013-04-04
Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME to file a joint proposed protective order to April 11, 2013 - filed by Actavis Inc., Millennium Pharmaceuticals Inc.. (Noreika,...
Entry #17 • 2013-04-03 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 15 STIPULATION TO EXTEND TIME for Parties to File a Joint Proposed Protective Order to April 4, 2013 filed by Millennium Pharmaceuticals Inc., Ac...
Entry #β€” • 2013-03-22
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Parties to File a Joint Proposed Protective Order to April 4, 2013 - filed by Actavis Inc., Millennium Pharmaceuticals Inc.. (Nor...
Entry #15 • 2013-03-21 Document →
Claim Construction / Markman Filing Pending
SO ORDERED, re (12 in 1:12-cv-01011-GMS, 15 in 1:12-cv-01490-GMS, 11 in 1:12-cv-01750-GMS) Proposed Order, filed by Millennium Pharmaceuticals Inc., Actavis Inc...
Entry #β€” • 2013-03-11

Docket Entries

(48 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Actavis Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 0311-1195801.) - filed by Millennium Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A - B, # 2 Civil Cover Sheet)(dzb, ) (Entered: 12/21/2012)

Entry #1 • 2012-12-21
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (dzb, ) (Entered: 12/21/2012)

Entry #2 • 2012-12-21
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/8/12. Date of Expiration of Patent: 1/25/22.Thirty Month Stay Deadline: 6/8/2015. (dzb, ) (Entered: 12/21/2012)

Entry #3 • 2012-12-21
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,713,446 B2; 6,958,319 B2;. (dzb, ) (Entered: 12/21/2012)

Entry #4 • 2012-12-21
1

Disclosure Statement pursuant to Rule 7.1 filed by Millennium Pharmaceuticals Inc. identifying Corporate Parent Takeda Pharmaceutical Company Limited for Millennium Pharmaceuticals Inc.. (dzb, ) (Entered: 12/21/2012)

Entry #5 • 2012-12-21
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc